| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Laboratoire de Cytologie Analytique, Faculté de Médecine, 69373 Lyon CEDEX 08 (JE 1879) [N. B., A. P., E. D., P. A. B., M. F.]; and Laboratoire dHématologie et de Cytogénétique, Hôpital Edouard-Herriot, 69003 Lyon [P. A. B., M. F.], France
Glucocorticoids inhibit cell proliferation by inducing cell cycle lengthening. In this report, we have analyzed, in normal peripheral blood lymphocytes, the involvement of p27Kip1in this slowing of proliferation. Following dexamethasone (DXM) treatment, p27Kip1 expression and regulation varied differently with the level of lymphocyte stimulation. In quiescent cells, DXM inhibited p27Kip1 protein expression by decreasing its rate of synthesis, whereas its half-life and mRNA steady state remained constant. In contrast, in stimulated lymphocytes, DXM increased p27Kip1 expression by enhancing its mRNA steady state. This increase is not only a consequence of the DXM-induced interleukin 2 inhibition: we also found an increase in p27Kip1 mRNA stability that was not observed in quiescent lymphocytes. Cyclin/cyclin-dependent kinase (CDK) complexes immunoprecipitated with p27Kip1 are differentially modified by DXM addition: (a) G1 kinasic complexes (cyclin D/CDK4 or CDK6) associated with p27Kip1 are strongly decreased by DXM, (b) S-phase complexes (CDK2/cyclin E and A) remained stable or increased, and (c) the association of p27Kip1 with the phosphorylated forms of CDK1 is increased by DXM. In addition, CDK2 kinase activity was decreased in DXM-treated cells: we suggest that p27Kip1 might participate in inhibiting its catalytic activity. These results indicated that, in normal lymphoid cells, p27Kip1 may be involved in DXM antiproliferative effects. The increase of p27Kip1 expression and a decrease in G1 mitogenic factors, together with the redistribution of p27Kip1 to S/G2-M regulatory complexes, may explain the lengthening of G1 and S/G2 after DXM treatment in lymphocytes.
This article has been cited by other articles:
![]() |
V. C Dhulipala, W. V Welshons, and C. S Reddy Cell cycle proteins in normal and chemically induced abnormal secondary palate development: a review Human and Experimental Toxicology, November 1, 2006; 25(11): 675 - 682. [Abstract] [PDF] |
||||
![]() |
T. Kogai, Y. Kanamoto, A. I. Li, L. H. Che, E. Ohashi, K. Taki, R. A. Chandraratna, T. Saito, and G. A. Brent Differential Regulation of Sodium/Iodide Symporter Gene Expression by Nuclear Receptor Ligands in MCF-7 Breast Cancer Cells Endocrinology, July 1, 2005; 146(7): 3059 - 3069. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Preclikova, V. Bryja, J. Pachernik, P. Krejci, P. Dvorak, and A. Hampl Early Cycling-independent Changes to p27, Cyclin D2, and Cyclin D3 in Differentiating Mouse Embryonal Carcinoma Cells Cell Growth Differ., September 1, 2002; 13(9): 421 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Madewell, S. Griffey, J. Walls, and R. Gandour-Edwards Reduced Expression of Cyclin-dependent Kinase Inhibitor p27Kip1 in Feline Lymphoma Vet. Pathol., November 1, 2001; 38(6): 698 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Rooney Cell Cycle Attenuation by p120E4F Is Accompanied by Increased Mitotic Dysfunction Cell Growth Differ., October 1, 2001; 12(10): 505 - 516. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhao, F.-C. Chang, and H. M. Furneaux The identification of an endonuclease that cleaves within an HuR binding site in mRNA Nucleic Acids Res., July 15, 2000; 28(14): 2695 - 2701. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wu, R. E. Bellas, J. Shen, W. Yang, and G. E. Sonenshein Increased p27Kip1 Cyclin-Dependent Kinase Inhibitor Gene Expression Following Anti-IgM Treatment Promotes Apoptosis of WEHI 231 B Cells J. Immunol., December 15, 1999; 163(12): 6530 - 6535. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |